Unlock AI power-ups — upgrade and save 20%!
Use code STUBE20OFF during your first month after signup. Upgrade now →

By Dr. Mary Claire Haver, MD
Published Loading...
N/A views
N/A likes
Cardiovascular Health Disparities in Women
📌 Heart disease is the leading cause of death for women, responsible for 1 in 3 deaths annually, yet only 44% of women recognized this in 2024 (down from 65% in 2009).
💔 Women often present with atypical heart attack symptoms (fatigue, nausea, jaw pain) instead of crushing chest pain, leading to potential misdiagnosis or dismissal (e.g., ruling out panic disorder).
🔬 Research and medical training often rely on the male model of disease, leading to a lack of sex-specific, gender-specific research and potentially harmful treatments, such as with beta-blockers post-heart attack in women.
📉 Atherosclerosis in women often presents as a studded pattern of plaques along arteries, causing decreased blood supply, unlike the single major blockage typical in men, resulting in vaguer symptoms.
Menopause, Hormones, and Risk Factors
🌡️ Perimenopausal symptoms, such as itchy ears or hot flashes, are indicators of increased heart disease risk due to fluctuating estrogen levels, not just quality-of-life issues.
⚡ Women having more hot flashes ( per week) showed a greater narrowing of their carotid arteries (increased stroke risk) compared to those with fewer flashes.
🧬 Lipoprotein(a) [Lp(a)], a highly atherogenic form of cholesterol, is under-discussed, and the recommendation to test it only once in a lifetime is based on data derived from men.
⚖️ Historically, hormone therapy trials (like the Women's Health Initiative) were flawed; subgroup analysis suggests estrogen-only therapy in women within 10 years of menopause or before age 60 showed a decreased rate of heart disease.
Systemic and Diagnostic Gaps
🗣️ Medical education often operates in silos, with cardiologists historically disconnected from fields like OBGYN, leading to a gap in understanding menopause as a cardiovascular risk factor.
📝 Terms like "geriatric" for pregnant women over 35 and "atypical" for women's heart symptoms demonstrate powerful, biased terminology that negatively impacts patient care and perception.
⏱️ Diagnostic delays are critical; while men presenting with classic symptoms proceed to intervention, women often wait for cardiac enzyme results and receive psychiatric referrals based on atypical presentation.
🩸 Calcium cardiac scoring is a useful risk predictor tool (score of 0 being ideal), but there is still uncertainty on setting cutoffs, particularly regarding initiating hormone therapy.
Actionable Lifestyle and Treatment Strategies
🏃 Movement is vital; the body needs utilization like a car, and lack of daily activity built into non-exercise routines increases risk.
💊 GLP-1 medications show benefits in decreasing heart failure risk and improving weight/cholesterol, but patients should view them as a long-term maintenance choice, similar to blood pressure pills.
🧪 For women in midlife, discussing hormone therapy (non-oral formulations like patches/gels) is crucial for symptom control *and* mitigating heart disease risk, which is often the greater, underappreciated benefit.
🩺 Women should aim for routine lipid panel screening at every annual physical exam starting at age 25, as women often rely solely on OBGYN visits focused on reproductive health.
Key Points & Insights
➡️ Advocate for sex-specific research, as data extrapolated from white men is actively leading to mismanagement and poorer outcomes for women (e.g., increased mortality on beta-blockers).
➡️ View perimenopausal symptoms (like hot flashes) as cardiovascular red flags, demanding proactive risk assessment rather than solely focusing on comfort or quality of life.
➡️ Physicians must break out of silos; cardiologists should integrate knowledge of menopause, and all practitioners must probe beyond "feeling fine" to assess cardiac risk related to hormonal changes.
➡️ Women should request screening for Lp(a), especially as new therapies for this genetic cholesterol risk factor are becoming available, and discuss non-oral hormone therapy for cardiovascular protection alongside symptom relief.
📸 Video summarized with SummaryTube.com on Feb 18, 2026, 18:42 UTC
Find relevant products on Amazon related to this video
As an Amazon Associate, we earn from qualifying purchases
Full video URL: youtube.com/watch?v=LlrUv6TIw5I
Duration: 1:24:18
Cardiovascular Health Disparities in Women
📌 Heart disease is the leading cause of death for women, responsible for 1 in 3 deaths annually, yet only 44% of women recognized this in 2024 (down from 65% in 2009).
💔 Women often present with atypical heart attack symptoms (fatigue, nausea, jaw pain) instead of crushing chest pain, leading to potential misdiagnosis or dismissal (e.g., ruling out panic disorder).
🔬 Research and medical training often rely on the male model of disease, leading to a lack of sex-specific, gender-specific research and potentially harmful treatments, such as with beta-blockers post-heart attack in women.
📉 Atherosclerosis in women often presents as a studded pattern of plaques along arteries, causing decreased blood supply, unlike the single major blockage typical in men, resulting in vaguer symptoms.
Menopause, Hormones, and Risk Factors
🌡️ Perimenopausal symptoms, such as itchy ears or hot flashes, are indicators of increased heart disease risk due to fluctuating estrogen levels, not just quality-of-life issues.
⚡ Women having more hot flashes ( per week) showed a greater narrowing of their carotid arteries (increased stroke risk) compared to those with fewer flashes.
🧬 Lipoprotein(a) [Lp(a)], a highly atherogenic form of cholesterol, is under-discussed, and the recommendation to test it only once in a lifetime is based on data derived from men.
⚖️ Historically, hormone therapy trials (like the Women's Health Initiative) were flawed; subgroup analysis suggests estrogen-only therapy in women within 10 years of menopause or before age 60 showed a decreased rate of heart disease.
Systemic and Diagnostic Gaps
🗣️ Medical education often operates in silos, with cardiologists historically disconnected from fields like OBGYN, leading to a gap in understanding menopause as a cardiovascular risk factor.
📝 Terms like "geriatric" for pregnant women over 35 and "atypical" for women's heart symptoms demonstrate powerful, biased terminology that negatively impacts patient care and perception.
⏱️ Diagnostic delays are critical; while men presenting with classic symptoms proceed to intervention, women often wait for cardiac enzyme results and receive psychiatric referrals based on atypical presentation.
🩸 Calcium cardiac scoring is a useful risk predictor tool (score of 0 being ideal), but there is still uncertainty on setting cutoffs, particularly regarding initiating hormone therapy.
Actionable Lifestyle and Treatment Strategies
🏃 Movement is vital; the body needs utilization like a car, and lack of daily activity built into non-exercise routines increases risk.
💊 GLP-1 medications show benefits in decreasing heart failure risk and improving weight/cholesterol, but patients should view them as a long-term maintenance choice, similar to blood pressure pills.
🧪 For women in midlife, discussing hormone therapy (non-oral formulations like patches/gels) is crucial for symptom control *and* mitigating heart disease risk, which is often the greater, underappreciated benefit.
🩺 Women should aim for routine lipid panel screening at every annual physical exam starting at age 25, as women often rely solely on OBGYN visits focused on reproductive health.
Key Points & Insights
➡️ Advocate for sex-specific research, as data extrapolated from white men is actively leading to mismanagement and poorer outcomes for women (e.g., increased mortality on beta-blockers).
➡️ View perimenopausal symptoms (like hot flashes) as cardiovascular red flags, demanding proactive risk assessment rather than solely focusing on comfort or quality of life.
➡️ Physicians must break out of silos; cardiologists should integrate knowledge of menopause, and all practitioners must probe beyond "feeling fine" to assess cardiac risk related to hormonal changes.
➡️ Women should request screening for Lp(a), especially as new therapies for this genetic cholesterol risk factor are becoming available, and discuss non-oral hormone therapy for cardiovascular protection alongside symptom relief.
📸 Video summarized with SummaryTube.com on Feb 18, 2026, 18:42 UTC
Find relevant products on Amazon related to this video
As an Amazon Associate, we earn from qualifying purchases

Summarize youtube video with AI directly from any YouTube video page. Save Time.
Install our free Chrome extension. Get expert level summaries with one click.